Medical AI

Sleep is now a bankable asset. A new wave of research is changing how high-stakes industries like aviation manage fatigue, turning rest into a strategic advantage.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

The federal government hails its new AI strategy as 'pro-worker,' but a major public service union warns it lacks crucial safeguards, risking jobs and services.

With key regulatory decisions pending in Canada and the US, DIAGNOS's CARA AI platform is set to unlock a multi-billion dollar market for early eye disease detection.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

A new partnership aims to revolutionize battery safety by sniffing out fires before they start. But can this defense-grade tech scale for our battery-powered world?

A new class of doctor is bridging the gap between lab and patient. Meet the physician-scientists tackling deadly diseases with revolutionary new approaches.

Senté renewed its pact with a top scientist. We explore how deep scientific partnerships are becoming the key differentiator in a crowded, hype-filled market.

Swedish innovator Triomed AB unveils a system that triples ultrafiltration in peritoneal dialysis, tackling a critical patient risk and challenging market leaders.

The 3rd annual National STEM Festival brings PhD-level student research to D.C., connecting young builders with leaders to solve real-world workforce shortages.

With record device sales providing a solid financial base, RenovoRx nears a critical milestone in its high-stakes Phase III trial for a new pancreatic cancer therapy.

As AI sweeps through medicine, Gigi Yuen-Reed's recognition highlights a crucial strategy: building systems that empower, not replace, human expertise.

A new diagnostic tool, Delve Detect, is using metagenomic sequencing to unmask elusive pathogens in the brain, offering hope where conventional tests fail.

With an FDA decision just weeks away, Ionis's olezarsen could redefine care for a debilitating condition, marking a pivotal moment for RNA-targeted medicine.

As Insulet unveils pivotal data, a deeper look reveals a strategy to not just improve tech, but to fundamentally change the daily reality of diabetes.

With its world-first gastric cancer drug heading for approval, Innovent Biologics isn't just offering new hope—it's executing a masterclass in strategic leverage.

Parnell's new Sevoflurane offering is more than a product line extension; it's a strategic move to become a one-stop-shop for veterinary anesthesia.

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

A new AI can detect Parkinson's progression where the current gold standard fails. In a stunning validation, the study was led by the very scientists who created the old method.

CHIGEE’s new XR-1 dash cam disappears into the bike, trading screens for voice alerts. We analyze if this minimalist approach is the future of rider safety.